Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 39-46

  Serralheiro, Ana ^a,b   Alves, Gilberto ^b,c   Fortuna, Ana ^a,b   Falcão, Amílcar ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Brain biodistribution; Intranasal administration; Lamotrigine; Mice; Nose to brain drug delivery; Pharmacokinetics

Indexed keywords

LAMOTRIGINE; TRIAZINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEASIBILITY STUDY; FRONTAL CORTEX; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NOSE TO BRAIN DRUG DELIVERY; OLFACTORY BULB; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BRAIN; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NOSE CAVITY; OLFACTORY SYSTEM; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; MALE; MICE; NASAL CAVITY; OLFACTORY PATHWAYS; TISSUE DISTRIBUTION; TRIAZINES;

EID: 84929996693     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.021     Document Type: Article

References (35)

1. T. Alam, J. Pandit, D. Vohora, M. Aqil, A. Ali, and Y. Sultana Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy Expert Opin. Drug Deliv. 12 2015 181 194
2. A.V. Alexopoulos Pharmacoresistant epilepsy: definition and explanation Epileptology 1 2013 38 42
3. S. Badgujar, M.A. Sontakke, D.R. Narute, R.R. Karmarkar, S.V. Tupkar, and S.D. Barhate Formulation and evaluation of sumatriptan succinate nasal in-situ gel using fulvic acid as novel permeation enhancer Int. J. Pharm. Res. Dev. 2 2010 39 52
4. W.A. Banks, J.E. Morley, M.L. Niehoff, and C. Mattern Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone J. Drug Target. 17 2009 91 97
5. U. Bergström, A. Franzén, C. Eriksson, C. Lindh, and E.B. Brittebo Drug targeting to the brain: transfer of picolinic acid along the olfactory pathways J. Drug Target 10 2002 469 478
6. V. Biton Pharmacokinetics: toxicology and safety of lamotrigine in epilepsy Expert Opin. Drug Metab. Toxicol. 2 2006 1009 1018
7. M.P. Canevini, G. De Sarro, C.A. Galimberti, G. Gatti, L. Licchetta, A. Malerba, G. Muscas, A. La Neve, P. Striano, and E. Perucca Relationship between adverse effects of antiepileptic drugs number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy Epilepsia 51 2010 797 804
8. M.M. Castel-Branco Caracterização neurofarmacocinética da lamotrigina em ratos 2002 Doctoral thesis University of Coimbra
9. K. Dave, and S. Purohit Formulation and in vitro characterization of intranasal mucoadhesive microspheres of lamotrigine using chitosan by gluteraldehyde cross linking Int. J. Pharm. Biol. Sci. 4 2013 402 415
10. European Medicines Agency, 2011. Guideline on bioanalytical method validation http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf.
11. European Parliament, Council of the European Union, 2010. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientifc purposes. Off. J. Eur. Union. 276, 33-79.
12. J.A. French Refractory epilepsy: clinical overview Epilepsia 48 2007 3 7
13. K.L. Goa, S.R. Ross, and P. Chrisp Lamotrigine - a review of its pharmacological properties and clinical efficacy in epilepsy Drugs 46 1993 152 176
14. V. Jogani, K. Jinturkar, T. Vyas, and A. Misra Recent patents review on intranasal administration for CNS drug delivery Recent Pat. Drug Deliv. Formul. 2 2008 25 40
15. L. Kozlovskaya, M. Abou-Kaoud, and D. Stepensky Quantitative analysis of drug delivery to the brain via nasal route J. Control. Release 189 2014 133 140
16. J.J. Lochhead, and R.G. Thorne Intranasal drug delivery to the brain M. Hammarlund-Udenaes, E.C.M. de Lange, R.G. Thorne, Drug delivery to the Brain - Physiological concepts, methodologies and approaches, AAPS Advances in the Pharmaceutical Sciences Series 10 2014 Springer New York 401 431
17. W. Löscher Drug transporters in the epileptic brain Epilepsia. 48 Suppl. 1 2007 8 13
18. C. Luna-Tortós, M. Fedrowitz, and W. Löscher Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 55 2008 1364 1375
19. H. Potschka Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches Pharmacogenomics 11 2010 1427 1438
20. H. Potschka Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach Pharmacolo. Ther. 125 2010 118 127
21. H. Potschka, and M.J. Brodie Pharmacoresistance H. Stefan, W.H. Theodore, Handbook of Clinical Neurology - Epilepsy Part II: Treatment 2012 Elsevier 741 757
22. H. Potschka, M. Fedrowitz, and W. Löscher P-Glycoprotein-mediated efflux of phenobarbital lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats Neurosci. Lett. 327 2002 173 176
23. Y. Schiller, and N. Krivoy Safety and efficacy of lamotrigine in older adults with epilepsy and co-morbid depressive symptoms Clin. Med. Ther. 1 2009 825 833
24. D. Schmidt, and W. Löscher Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms Epilepsia 46 2005 858 877
25. I.R. Schmolka Artificial Skin I. Preparation and properties of pluronic F-127 gels for treatment of burns J. Biomed. Mater. Res 6 1972 571 582
26. A. Serralheiro, G. Alves, A. Fortuna, and A. Falcão Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting Eur. J. Pharm. Sci. 60 2014 32 39
27. A. Serralheiro, G. Alves, J. Sousa, A. Fortuna, and A. Falcão Nose as route for drug delivery T.M. Önerci, Nasal Physiology and Pathophysiology of Nasal Disorders 2013 Springer Heidelberg 191 215
28. S.D. Shorvon Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009 Epilepsia 50 Suppl. 3 2009 93 130
29. N.G.N. Swamy, and Z. Abbas Mucoadhesive in situ gels as nasal drug delivery systems: an overview Asian J. Pharm. Sci. 7 2012 168 180
30. US Food and Drug Administration, 2001. Guidance for industry: Bioanalytical method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
31. M.C. Walker, X. Tong, H. Perry, M.S. Alavijeh, and P.N. Patsalos Comparison of serum: cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine Br. J. Pharmacol. 130 2000 242 248
32. F. Wang, X. Jiang, and W. Lu Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats Int. J. Pharm. 263 2003 1 7
33. D.F. Weaver Design of innovative therapeutics for pharmacoresistant epilepsy: challenges and needs Epilepsia 54 Suppl. 2 2013 56 59
34. D.F. Weaver, and B. Pohlmann-Eden Pharmacoresistant epilepsy: unmet needs in solving the puzzle(s) Epilepsia 54 Suppl. 2 2013 80 85
35. C. Zhang, P. Kwan, Z. Zuo, and L. Baum The transport of antiepileptic drugs by P-glycoprotein Adv. Drug Deliv. Rev. 64 2012 930 942